After initiating a wind-down more than 18 months ago and exploring liquidation, Galera Therapeutics has found a path forward ...

Strong demand for GLP-1 drugs and next-gen diagnostic testing is pulling investors back into life sciences, even as AI soaks ...

A slow start to 2026 has put first-time biotech financings on course for their worst year since before the pandemic, reducing ...

The high-profile obesity drug developer priced the biotech sector’s biggest offering in years and will use the proceeds to ...

Smaller acquisitions and disciplined pricing are proving to be big benefits to a wider number of companies ...

Seaport Therapeutics, a Boston biotech led by Daphne Zohar, has filed to go public, setting up a Nasdaq debut that could funnel fresh cash into its neuropsychiatric drug pipeline. Spun out of PureTech ...

Equipped with $300 million, Beeline has an oral medicine for the treatment of lupus as well as other experimental drugs ...

-- PanGIA Analysis System, a novel machine learning platform for non-invasive diagnosis of oral cancer through an oral sample -- PanGIA Analysis System, a novel machine learning platform for ...

For decades, venture capitalists have relied on a tried-and-true recipe to make money in biotech. Now that approach is being ...

Biogen could see lower royalties for Ocrevus after its patent expires , but it has developed other medicines that will ...

Biotech stocks surged in 2025, driven by FDA approvals, M&A activity, and rising longevity investment. Explore key trends, ...

In this article, we will look at the 8 Most Undervalued Biotech Stocks to Buy Right Now. On April 13, Tom Lee, Fundstrat’s ...